IDXX

IDEXX Laboratories, Inc. - 10-Q Summary (Period Ended June 30, 2009)

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for IDEXX Laboratories, Inc., a provider of diagnostic products and services for the veterinary, water quality, production animal, and human medical markets. The reporting period covers the three and six months ended June 30, 2009. The company operates primarily through three reportable segments: Companion Animal Group (CAG), Water, and Production Animal Segment (PAS).

Key Financial Metrics

Note: Debt figures reflect the revolving credit facility balance. At June 30, 2009, $80 million was classified as long-term.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 5.2% year-over-year. The decline was driven by a 5.0% drop in the CAG segment, a 5.3% drop in Water, and an 11.1% drop in PAS. The CAG decline was significantly impacted by the divestiture of pharmaceutical assets in late 2008, which removed approximately $17.5 million in revenue compared to the prior year.
• Margin Compression: Gross margin decreased to 52.3% from 53.1%. This was primarily due to the absence of higher-margin pharmaceutical sales, lower production volumes increasing unit costs, and a shift in sales mix toward lower-margin services and instruments.
• Operating Expenses: Total operating expenses decreased 4.5% to $175.3 million. Reductions were seen across all segments, largely due to the pharmaceutical divestiture, favorable foreign currency impacts on expenses, and cost containment measures.
• Cash Flow: Operating cash flow increased 4.0% to $70.9 million despite lower net income, driven by improved working capital management (specifically smaller reductions in accounts payable and less cash used for accounts receivable).

Outlook, Risks, and Management Commentary

• Economic Impact: Management attributes the revenue decline to a weak global economy, resulting in fewer patient visits to veterinary clinics and reduced demand for elective procedures and capital equipment. Non-regulatory water testing volumes also declined due to reduced new home construction.
• Divestiture Impact: The company sold a substantial portion of its pharmaceutical business in Q4 2008. This transaction significantly reduced revenue and operating expenses in the current period compared to the prior year.
• Capital Allocation: The company continued its share repurchase program, spending $39.7 million to repurchase 1.1 million shares in the first six months of 2009. Capital expenditures were reduced to $21.1 million for the period, with a full-year 2009 plan of $55-$60 million.
• Risks: Key risks include the potential for further economic downturns affecting pet owner spending, foreign currency exchange rate fluctuations (approx. 23% of revenue is international), and dependence on a limited number of suppliers for proprietary components.

Investor Verification Checklist

• Pharmaceutical Divestiture: Verify the long-term impact of the Q4 2008 pharmaceutical asset sale on future revenue growth and margin structure.
• Distributor Inventory: Monitor distributor inventory levels, as fluctuations can distort reported revenue growth relative to actual end-user demand.
• Foreign Currency Exposure: Assess the impact of a strengthening U.S. dollar on international margins, given that 23% of revenue is derived from U.S. manufacturing sold internationally.
• Capital Expenditures: Track the $16 million renovation of the Westbrook, Maine headquarters facility against the total capital budget.
• Debt Covenants: Confirm continued compliance with the debt-to-EBITDA covenant (3-to-1) under the revolving credit facility.